Skip to content Skip to sidebar Skip to footer

Parkinson’s Disease: A Comprehensive Academic Resource

An evidence-based, rigorously cited guide to understanding Parkinson’s disease — from molecular genetics to emerging therapies. Designed for patients, caregivers, students, and healthcare professionals.


Understanding the Second Most Common Neurodegenerative Disease

Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects over 8.5 million people worldwide, making it the fastest-growing neurological condition in the world (World Health Organization, 2023; Dorsey et al., Journal of Parkinson’s Disease, 2018). The disease is characterized by the loss of dopamine-producing neurons in the substantia nigra pars compacta, leading to a complex constellation of motor and non-motor symptoms that profoundly impact quality of life.

This resource synthesizes findings from the world’s most authoritative sources — including the National Institutes of Health (NIH/NINDS), the Movement Disorder Society (MDS), the Parkinson’s Foundation, the Michael J. Fox Foundation, Mayo Clinic, Johns Hopkins Medicine, Cleveland Clinic, the World Health Organization, and leading peer-reviewed journals — to provide a comprehensive, academically rigorous overview of every facet of the disease.

Site Chapters

🧠 Foundation

⭐ Featured Chapters

  • The Genetics of Parkinson’s Disease — Comprehensive coverage of all implicated genes (SNCA, LRRK2, GBA1, PINK1, PRKN, and 30+ more), PARK loci, GWAS discoveries, gene therapy, precision medicine, and genetic counseling
  • Natural & Unconventional Treatments — Evidence-based analysis of 40+ complementary therapies including herbal remedies, dietary approaches, mind-body practices, acupuncture, photobiomodulation, and emerging experimental approaches

💊 Treatment

🤝 Living & Support

🔬 Research & Resources

📋 Key Statistics

  • 8.5+ million people affected worldwide (WHO, 2023)
  • 1+ million living with PD in the United States (Parkinson’s Foundation, 2024)
  • Fastest-growing neurological condition globally (GBD Study, 2019)
  • 5-10% of cases are monogenic (genetic) forms
  • 134+ genetic risk loci identified via GWAS (GP2, 2025)
  • ~50% of PD patients use complementary therapies

Citation Methodology

Every factual claim on this website is supported by peer-reviewed scientific literature, authoritative medical institutions, or established clinical guidelines. References follow a modified APA format with hyperlinks to original sources (PubMed, DOI) wherever available. This resource is intended for educational purposes and does not constitute medical advice. Always consult a qualified healthcare professional for personal medical decisions.

Primary Sources Analyzed

This website’s structure and content are informed by systematic analysis of the 20 most authoritative global Parkinson’s disease resources: Mayo Clinic, Cleveland Clinic, Johns Hopkins Medicine, Parkinson’s Foundation, Michael J. Fox Foundation, American Parkinson Disease Association, Davis Phinney Foundation, NIH/NINDS, World Health Organization, NHS UK, MedlinePlus, WebMD, Parkinson’s UK, Parkinson’s Europe (EPDA), Movement Disorder Society, World Parkinson Coalition, PubMed/NCBI, Stanford Medicine, PMD Alliance, and the National Council on Aging.